Consistent with this, higher CSF sTREM2 levels that relate to higher CSF t-tau and p-tau levels at the preclinical AD stage was associated with greater cognitive decline, unlike in the dementia stage, in which higher CSF sTREM2 levels were associated with slower cognitive decline (Figure 2). This evidence concerns the gene MAPT and dementia.